It is recommended that asparaginase be administered to patients only in a hospital setting under the supervision of a physician who is qualified by training and experience to administer cancer chemotherapeutic agents, because of the possibility of severe reactions, including anaphylaxis and sudden death. The physician must be prepared to treat anaphylaxis at each administration of the drug. In the treatment of each patient the physician must weigh carefully the possibility of achieving therapeutic benefit versus the risk of toxicity.
Special handling procedures should be followed (see DOSAGE AND ADMINISTRATION, Special Handling).
ELSPAR * (Asparaginase) contains the enzyme L-asparagine amidohydrolase, type EC-2, derived from
It is a white crystalline powder that is freely soluble in water and practically insoluble in methanol, acetone and chloroform. Its activity is expressed in terms of International Units (I.U.) according to the recommendation of the International Union of Biochemistry. The specific activity of ELSPAR is at least 225 I.U. per milligram of protein and each vial contains 10,000 I.U. of asparaginase and 80 mg of mannitol, an inactive ingredient, as a sterile, white lyophilized plug or powder for intravenous or intramuscular injection after reconstitution.
ELSPAR is indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. ELSPAR should not be used as the sole induction agent unless combination therapy is deemed inappropriate. ELSPAR is not recommended for maintenance therapy.
Media Articles Related to Elspar (Asparaginase)
UCSF-led study explains how early childhood vaccination reduces leukemia risk
Source: Immune System / Vaccines News From Medical News Today [2015.05.19]
Chronic infections push 'pre-leukemia' cells, common in newborns, into malignancyA team led by UCSF researchers has discovered how a commonly administered vaccine protects against acute...
Minimal residual disease alone not predictive in T-cell leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.05.15]
Children achieve complete remission despite few remaining leukemia cells following chemotherapyThis image shows T-cell acute lymphoblastic leukemia.
Signaling pathway revealed through which a promising anti-leukemia drug kills cancer cells
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.05.15]
Knowing how the drug, called JQ1, works to repress protein BRD4 will help make the drug more powerfulInhibiting a protein called BRD4 critical to the survival of acute myeloid leukemia (AML)...
TSRI researchers connect haywire protein to breast cancer, leukemia
Source: Breast Cancer News From Medical News Today [2015.05.11]
A new study led by scientists at The Scripps Research Institute (TSRI) sheds light on the cause of some cancers, including breast cancer and leukemia.
Investigational medicine venetoclax receives Breakthrough Therapy Designation in relapsed or refractory chronic lymphocytic leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.05.08]
AbbVie has announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted...
Published Studies Related to Elspar (Asparaginase)
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. [2011.04]
l-asparaginase encapsulated within erythrocytes (GRASPA((R)) ) should allow serum asparagine depletion over a longer period than the native form of the enzyme, using lower doses and allowing better tolerance. The GRASPALL 2005-01 study, a multicentre randomized controlled trial, investigated three doses of GRASPA((R)) for the duration of asparagine depletion in a phase I/II study in adults and children with acute lymphoblastic leukaemia (ALL) in first relapse.
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. [2010.05]
We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial. VT occurred in 59/1824 (3.2%) patients recruited over 5 years with 90% occurring during a period of Asparagine depletion... This report confirms a significant risk of thrombosis with such therapy, but demonstrates that re-exposure to Asparaginase is feasible and safe.
Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. [2009.12]
Asparaginase (ASP) is used routinely in frontline clinical trials for the treatment of childhood acute lymphoblastic leukemia (ALL). The goals of this study were to assess the pharmacokinetics and pharmacodynamics of ASP and to mathematically model the dynamics between ASP and asparagine (ASN) in relapsed ALL...
Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. [2008.12.15]
The pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant Escherichia coli-asparaginase preparation was compared with Asparaginase medac. Thirty-two children with acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5000 U/m(2) every 3 days, for a total of 8 doses during induction treatment...
Pharmacokinetics, pharmacodynamics, efficacy and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia- a randomized phase II clinical trial. [2008.09.19]
The pharmacokinetics, pharmacodynamics, efficacy and safety of a new recombinant E.coli-asparaginase preparation was compared to the commercially available asparaginase preparation Asparaginase medac(TM). 32 children with de novo ALL were randomized to receive one of both agents at a dose of 5,000 U/m(2) every 3 days for a total of 8 doses during induction treatment...
Clinical Trials Related to Elspar (Asparaginase)
Erwinase Study in Patients With Acute Lymphoblastic Leukemia [Recruiting]
The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase
(Erwinase®) as a replacement for patients who are allergic to E. coli L-asparaginase or
Pegylated E. coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy [Recruiting]
This study will utilize Erwinaze via intravenous administration in patients between the
ages of 1 and 30 who have experienced an allergy to their frontline therapy. The study will
determine the proportion of patients with 2 day nadir serum asparaginase activity levels
that are >0. 1 IU/mL during the first 2 weeks of treatment with 3 times per week IV dosing.
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Patients (Adults/Children) With Relapse of Acute Lymphoblastic Leukemia [Recruiting]
This study is run to confirm the benefit/risk profile of GRASPA® at 150 IU/kg in combination
with the COOPRALL regimen in adults and children patients with relapsed ALL, with or without
known hypersensitivity to L-asparaginase.
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage [Recruiting]
Erwinase Master Treatment Protocol [Available]
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic
leukemia (ALL) who have had previous allergic reactions to certain formulations of
Reports of Suspected Elspar (Asparaginase) Side Effects
Toxicity TO Various Agents (14),
Embolism Venous (11),
OFF Label USE (10),
Death (8), more >>
Page last updated: 2015-05-19